Archives
-
Chloroquine in Cancer Research: Review and Limits
2026-10-12
A 2024 narrative review examines how Chloroquine may influence cancer biology through autophagy-dependent and autophagy-independent pathways. Its synthesis supports mechanistic interest and combination-therapy hypotheses, but heterogeneous preclinical evidence and unresolved clinical translation limit conclusions about therapeutic benefit.
-
VDR, Erastin, and Ferroptosis in Cisplatin AKI
2026-10-11
A preclinical study links VDR activation with protection from cisplatin-induced acute kidney injury through a GPX4-associated ferroptosis pathway. The evidence is mechanistically suggestive but remains limited to cellular and animal models, and it does not establish clinical benefit or generalize directly to cancer biology.
-
Atorvastatin and Ferroptosis in HCC: Paper Analysis
2026-10-10
Wang and colleagues combined a ferroptosis-related prognostic signature with Connectivity Map screening to identify Atorvastatin as a candidate for hepatocellular carcinoma research. Their computational and preclinical findings support a testable link between Atorvastatin exposure, ferroptosis-associated biology, and reduced HCC growth and migration, while remaining insufficient to establish clinical efficacy.
-
Cyclosporin A: Evidence, Mechanisms, and Research Limits
2026-10-09
Cyclosporin A, also known as cyclosporine, is a cyclophilin-targeting immunomodulator used to investigate calcineurin-NFAT signaling, mitochondrial permeability, apoptosis modulation, and disease-associated inflammation. This overview separates supplier-reported properties from published findings and explains where evidence remains model-specific or insufficient.
-
Romidepsin (FK228): Evidence, Mechanisms and Limits
2026-10-09
Romidepsin (FK228) is best understood as a research probe for class I histone deacetylase biology, with supplier-reported activity against HDAC1 and HDAC2 and downstream effects that may include altered transcription, cell-cycle regulation, and apoptosis. This overview separates those catalog claims from findings in a 2026 pre-proof study of Platycodin D, whose RFC4–Notch mechanism should not be transferred to Romidepsin without direct evidence.
-
Amiloride (MK-870): Evidence, Interpretation and Limits
2026-10-08
A source-grounded overview of Amiloride (MK-870) as a pharmacological research probe, explaining its proposed ion-transport relevance, how inhibitor evidence should be interpreted, and why the supplied nanovaccine study cannot establish claims about Amiloride.
-
PXDN, LDHA, and Glycolysis in Glioblastoma
2026-10-08
A 2026 study identifies peroxidasin (PXDN) as a glycolysis-associated driver of glioblastoma progression and links its effects to lactate dehydrogenase A (LDHA). Integrated transcriptomic analysis, cellular assays, and an in vivo model support a PXDN–LDHA relationship, while the study remains preclinical and requires validation in independent patient cohorts.
-
Caspase-3 Colorimetric Assay Kit Overview
2026-10-07
A supplier-described biochemical assay for DEVD-dependent caspase-3 activity. No matched paper evidence was supplied, so performance and application claims remain unverified here.
-
Caspase-3 Colorimetric Assay Kit Overview
2026-10-07
A concise, source-limited overview of APExBIO K2008, describing its documented DEVD-dependent caspase-3 activity readout and the absence of matched paper evidence.
-
Midecamycin: From Ribosome Mechanism to Translation
2026-10-06
A source-grounded perspective on Midecamycin as an acetoxy-substituted macrolide antibiotic, integrating ribosomal mechanism, reported susceptibility patterns, macrolide pharmacology, resistance biology, and translational strategy without overstating evidence.
-
MDockPeP2_VS and Peptide Inhibitors of β-Lactamase
2026-10-06
Xu and colleagues introduced MDockPeP2_VS, a structure-based computational framework that uses structural conservation to make large-scale peptide screening more tractable. In a proof-of-concept application to TEM-1 β-lactamase, one of the ten computationally prioritized peptides, TF7, showed measurable inhibition with a reported Ki of 1.37 ± 0.37 μM, while the study also defines important boundaries around computational ranking and biochemical validation.
-
EZH2 Inhibition and 5-AzaC in PTEN-Deficient GBM
2026-10-05
A 2025 Journal for ImmunoTherapy of Cancer study reports that EZH2 inhibition enables 5-AzaC to reactivate endogenous retroviral elements and restore type I interferon signaling in PTEN-deficient glioblastoma. The findings provide a mechanistic explanation for why 5-AzaC monotherapy may be insufficient in this context while supporting a preclinical rationale for combined epigenetic and immune-directed strategies.
-
α-Linolenic Acid: Research Context and Evidence
2026-10-05
α-Linolenic Acid (ALA) is an essential omega-3 fatty acid studied in lipid metabolism, cardiovascular biology, inflammation, and cancer research. This overview separates established biochemical context from hypotheses and distinguishes ALA evidence from a 2025 arachidonic-acid vaccine study that should not be generalized to ALA.
-
Syringin in RCC: EGFR/PI3K/Akt and Sunitinib
2026-10-04
This 2024 Journal of Functional Foods study investigates Syringin as a potential sensitizer for sunitinib-resistant renal cell carcinoma through EGFR/PI3K/Akt pathway modulation. Its combined computational and cell-based evidence supports further mechanistic research, but does not establish clinical efficacy or a treatment regimen.
-
Hazelnut Protein Oxidation: AAPH Study Insights
2026-10-03
A 2024 study compared AAPH, malondialdehyde, and hydrogen peroxide as distinct oxidation inputs in hazelnut proteins, linking each to different changes in solubility, interfacial functionality, and gel structure. Its main contribution is a comparative structure–function framework showing that oxidation cannot be interpreted as a single, uniform protein-modification process.